Case 1: Suspected Maturity-Onset Diabetes of the Young (MODY)-5 (MODY-HNF1B) Responding to Monotherapy With Metformin
Abstract
A thinly built 40-year-old Caucasian man with a past medical history of weight loss, polyuria, and polydipsia was admitted with sudden-onset mild epigastric pain, nausea, dizziness, lightheadedness, and excessive thirst. He also had hyperglycemia, hyponatremia, and elevated transaminases and serum creatinine. Hyperglycemia and hyponatremia resolved after intravenous (IV) hydration and IV insulin. However, he had persistently elevated creatinine and abnormal liver function tests upon discharge the following day and was instructed to establish care with Endocrinology.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.